Drug Profile
Research programme: rheumatoid arthritis therapy - MediGene AG
Alternative Names: EndoMTXLatest Information Update: 30 Aug 2010
Price :
$50
*
At a glance
- Originator MediGene AG
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 04 Feb 2007 Preclinical trials in Rheumatoid arthritis in Germany (unspecified route)